TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06835569: A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Sponsor: Alterome Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 448 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06835569 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06835569 Rescue Dossier →